海正药业
(600267)
| 流通市值：104.00亿 | | | 总市值：104.84亿 |
| 流通股本：11.98亿 | | | 总股本：12.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,874,540,640.41 | 5,243,468,128.1 | 2,726,615,253.7 | 10,373,071,956.92 |
| 营业收入 | 7,874,540,640.41 | 5,243,468,128.1 | 2,726,615,253.7 | 10,373,071,956.92 |
| 二、营业总成本 | 7,323,584,992.31 | 4,907,475,802.86 | 2,578,018,340.82 | 10,134,419,762.12 |
| 营业成本 | 4,632,200,445.07 | 3,179,032,890.99 | 1,740,824,816.68 | 6,188,820,795.6 |
| 税金及附加 | 77,046,271.19 | 43,918,631.6 | 26,911,175.38 | 84,942,223.31 |
| 销售费用 | 1,583,085,460.85 | 999,873,586.74 | 470,410,988.15 | 2,368,357,495.82 |
| 管理费用 | 667,223,152.78 | 434,579,174.8 | 212,740,662.21 | 908,672,800.91 |
| 研发费用 | 262,633,894.43 | 177,546,214.57 | 89,183,595.29 | 391,953,184.73 |
| 财务费用 | 101,395,767.99 | 72,525,304.16 | 37,947,103.11 | 191,673,261.75 |
| 其中:利息费用 | 123,269,108.14 | 87,506,144.38 | 46,821,956.82 | 215,402,480.88 |
| 其中:利息收入 | 20,265,246.08 | 15,030,557.44 | 9,682,652.49 | 23,165,353.65 |
| 加:公允价值变动收益 | -13,227,309.09 | -116,840.31 | -21,808.83 | 278,292.28 |
| 加:投资收益 | 181,056,163.81 | 170,208,529.96 | 122,620,672.11 | 66,055,662.43 |
| 资产处置收益 | 1,737,175.59 | 2,682,933.65 | -7,150.39 | -11,491,146.77 |
| 资产减值损失(新) | -186,768,005.6 | -72,741,345.86 | -32,274,913.03 | -285,521,664.88 |
| 信用减值损失(新) | -15,108,301.56 | -20,320,046.66 | -2,199,257.28 | -23,477,458.95 |
| 其他收益 | 87,779,410.47 | 72,365,112.45 | 36,166,575.74 | 104,947,092.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 606,424,781.72 | 488,070,668.47 | 272,881,031.2 | 89,442,971.17 |
| 加:营业外收入 | 6,326,176.69 | 2,252,079.36 | 263,402.53 | 1,721,298.11 |
| 减:营业外支出 | 7,230,702.78 | 4,758,577.09 | 2,555,290.75 | 174,031,000.86 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 605,520,255.63 | 485,564,170.74 | 270,589,142.98 | -82,866,731.58 |
| 减:所得税费用 | 95,235,241.44 | 51,534,699.81 | 24,239,150.13 | 14,148,229.93 |
| 六、净利润 | 510,285,014.19 | 434,029,470.93 | 246,349,992.85 | -97,014,961.51 |
| 持续经营净利润 | 510,285,014.19 | 434,029,470.93 | 246,349,992.85 | -97,014,961.51 |
| 归属于母公司股东的净利润 | 515,312,975.68 | 435,241,383.97 | 248,531,288.09 | -93,171,306.6 |
| 少数股东损益 | -5,027,961.49 | -1,211,913.04 | -2,181,295.24 | -3,843,654.91 |
| (一)基本每股收益 | 0.44 | 0.37 | 0.21 | -0.08 |
| (二)稀释每股收益 | 0.44 | 0.37 | 0.21 | -0.08 |
| 八、其他综合收益 | -512,365.67 | -1,082,846.91 | -717,310.31 | 1,311,827.06 |
| 归属于母公司股东的其他综合收益 | -512,365.67 | -1,082,846.91 | -717,310.31 | 1,311,827.06 |
| 九、综合收益总额 | 509,772,648.52 | 432,946,624.02 | 245,632,682.54 | -95,703,134.45 |
| 归属于母公司股东的综合收益总额 | 514,800,610.01 | 434,158,537.06 | 247,813,977.78 | -91,859,479.54 |
| 归属于少数股东的综合收益总额 | -5,027,961.49 | -1,211,913.04 | -2,181,295.24 | -3,843,654.91 |
| 公告日期 | 2024-10-31 | 2024-08-20 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 保留意见 |